Statins for treatment of CNS diseases. Status report from research and clinical practice;Statine zur behandlung von erkrankungen des zentralen nervensystems. Eine standortbestimmung aus forschung und klinik

Nervenarzt

Volumn 76, Issue 4, 2005, Pages 426-437

  Menge, T ^a   Von Budingen H C ^b   Zamvil, S S ^a   Hartung, H P ^c   Kieseier, B C ^c   Stuve O ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; HMG CoA reductase inhibitors; Ischemic stroke; Multiple sclerosis; Statins

Indexed keywords

ATORVASTATIN; BETA INTERFERON; CONTRAST MEDIUM; FLUINDOSTATIN; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MEDICAL RESEARCH; METABOLITE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN PROCESSING; REVIEW; TRANSIENT ISCHEMIC ATTACK;

BIOMEDICAL RESEARCH; BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 23944492952     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1806-4     Document Type: Review

References (87)

1. Anonymous (1995) Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346:1647-1653
2. Aktas O, Waiczies S, Smorodchenko A et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197:725-733
3. Amarenco P, Bogousslavsky J, Callahan AS et al. (2003) Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 16:389-395
4. Amarenco P, Lavallee P, Touboul PJ (2004) Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3:271-278
5. Atkins D, Psaty BM, Koepsell TD et al. (1993) Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 119:136-145
6. Bellosta S, Ferri N, Bernini F et al. (2000) Non-lipid-related effects of statins. Ann Med 32:164-176
7. Bellosta S, Via D, Canavesi M et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678
8. Black DM, Bakker-Arkema RG, Nawrocki JW (1998) An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 158:577-584
9. Byington RP, Davis BR, Plehn JF et al. (2001) Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 103:387-392
10. Chen J, Zhang ZG, Li Y et al. (2003) Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53:743-751
11. Chopp M, Zhang RL, Chen H et al. (1994) Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 25:869-875
12. Collins R, Armitage J, Parish S et al. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
13. Crisby M, Nordin-Fredriksson G, Shah PK et al. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103:926-933
14. Davidson MH (2001) Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 61:197-206
15. Dirnagl U, ladecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397
16. Duda PW, Schmied MC, Cook SL et al. (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105:967-976
17. Endres M, Laufs U, Huang Z et al. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-8885
18. Fassbender K, Simons M, Bergmann C et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861
19. Fassbender K, Stroick M, Bertsch T et al. (2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59:1257-1258
20. Frears ER, Stephens DJ, Walters CE et al. (1999) The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10:1699-1705
21. Fukumoto Y, Libby P, Rabkin E et al. (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103:993-999
22. Gaist D, Garcia Rodriguez LA, Huerta C et al. (2001) Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56:931-933
23. Gaist D, Jeppesen U, Andersen M et al. (2002) Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337
24. Ganne F, Vasse M, Beaudeux JL et al. (2000) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 84:680-688
25. Gearing M, Mori H, Mirra SS (1996) Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39:395-399
26. Gertz K, Laufs U, Lindauer U et al. (2003) Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34:551-557
27. Ginsberg HN (1998) Effects of statins on triglyceride metabolism. Am J Cardiol 81:32B-35B
28. Glomset JA, Gelb MH, Farnsworlh CC (1990) Prenyl proteins in eukaryotic cells: a new lype of membrane anchor. Trends Biochem Sci 15:139-142
29. Greenwood J, Walters CE, Pryce G et al. (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907
30. Greisenegger S, Mullner M, Tentschert S et al. (2004) Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 221:5-10
31. Hachinski V, Graffagnino C, Beaudry M et al. (1996) Lipids and stroke: a paradox resolved. Arch Neurol 53:303-308
32. Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159-168
33. Hoglund K, Wiklund O, Vanderstichele H (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61:333-337
34. Iwatsubo T, Odaka A, Suzuki N et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45-53
35. Jick H, Zornberg GL, Jick SS et al. (2000) Statins and the risk of dementia. Lancet 356:1627-1631
36. Jonsson N, Asplund K (2001) Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 32:1112-1115
37. Kallen J, Welzenbach K, Ramage P et al. (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292:1-9
38. Kastelein JJ, de Groot E, Sankatsing R (2004) Atherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progression. Am J Med 116(Suppl 6A):31S-36S
39. Kieseier BC, Archelos JJ, Hartung HP (2004) Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 61:929-932
40. Kimura M, Kurose I, Russell J et al. (1997) Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 17:1521-1526
41. Kobashigawa JA, Katznelson S, Laks H et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627
42. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282:2340-2346
43. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423
44. Lehr HA, Seemuller J, Hubner C et al. (1993) Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor. Arterioscler Thromb 13:1013-1018
45. Leung BP, Sattar N, Crilly A et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524-1530
46. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110:285-288
47. Liu T, McDonnell PC, Young PR et al. (1993) Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 24:1746-1750
48. Locatelli S, Lutjohann D, Schmidt HH et al. (2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59:213-216
49. Maltese WA (1990) Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4:3319-3328
50. Marti-Fabregas J, Gomis M, Arboix A et al. (2004) Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35:1117-1121
51. Matsumoto M, Einhaus D, Gold ES et al. (2004) Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 172:7377-7384
52. McKay A, Leung BP, McInnes IB et al. (2004) A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172:2903-2908
53. Monick MM, Powers LS, Butler NS et al. (2003) Inhibition of Rho family GTPases results in increased TNF-alpha production after lipopolysaccharide exposure. J Immunol 171:2625-2630
54. Montero MT, Hernandez O, Suarez Y et al. (2000) Hydroxymethylglutaryl- coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153:303-313
55. Naidu A, Xu Q, Catalano R et al. (2002) Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res 958:100-111
56. Nath N, Giri S, Prasad R et al. (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273-1286
57. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997
58. Neuhaus O, Wiendl H, Kieseier BC et al. (2003) [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators]. Nervenarzt 74:704-707
59. Notarbartolo A, Davi G, Averna M et al. (1995) Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:247-251
60. Opper C, Clement C, Schwarz H et al. (1995) Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 113:211-217
61. Pahan K, Sheikh FG, Namboodiri AM et al. (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671-2679
62. Polman CH, Killestein J (2004) Statins for the treatment of multiple sclerosis: cautious hope. Lancet 363:1570
63. Quan Sang KH, Levenson J, Megnien JL et al. (1995) Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol 15:759-764
64. Refolo LM, Malester B, LaFrancois J et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321-331
65. Ridker PM (2002) Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation 105:2583-2585
66. Rockwood K, Kirkland S, Hogan DB et al. (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223-227
67. Romano M, Diomede L, Sironi M et al. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80:1095-110O
68. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
69. Sena A, Pedrosa R, Graca MM (2003) Therapeutic potential of lovastatin in multiple sclerosis. J Neural 250:754-755
70. Simons M, Keller P, De Strooper B et al. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464
71. Simons M, Schwarzler F, Lutjohann D et al. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52:346-350
72. Sparks DL, Scheff SW, Hunsaker JC et al. (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94
73. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540
74. Stanislaus R, Pahan K, Singh AK et al. (1999) Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 269:71-74
75. Stanislaus R, Singh AK, Singh I (2001) Lovastatin treatment decreases mononuclearcell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162
76. Stuve O, Dooley NP, Uhm JH et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40:853-863
77. Thomas T, Thomas G, McLendon C et al. (1996) Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168-171
78. Vega GL, Weiner MF, Lipton AM et al. (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60:510-515
79. Vollmer T, Key L, Durkalski V et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608
80. Weber C, Erl W, Weber KS et al. (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30:1212-1217
81. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692
82. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183-200
83. Wolozin B, Kellman W, Ruosseau P et al. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443
84. Woo D, Kissela BM, Khoury JC et al. (2004) Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 35:1360-1364
85. Xu J, Chen S, Ahmed SH et al. (2001) Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 21:RC118
86. Yankner BA, Dawes LR, Fisher S et al. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245:417-420
87. Youssef S, Stuve O, Patarroyo JC et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84